Liquid Biopsy: From Discovery to Clinical Application

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Research

Background:

• Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have emerged as significant biomarkers in translational cancer research over the last decade.
• Despite their inclusion in numerous clinical trials, the full clinical utility of CTCs and ctDNA is still under active investigation, with early results showing considerable promise.

Purpose of the Study:

• To propose a conceptual framework for circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) assays.
• To identify and discuss current challenges in CTC and ctDNA research to help structure this evolving field.
• To highlight the potential clinical applications of liquid biopsy in oncology.

Main Methods:

• Conceptual framework development for CTC and ctDNA assays.
• Review and analysis of current challenges in CTC and ctDNA research.
• Literature review on the clinical applications and significance of liquid biopsy.

Main Results:

• CTCs and ctDNA are recognized as key biomarkers with growing attention in translational research.
• Clinical applications span early cancer detection, staging, relapse prediction, therapy monitoring, and resistance mechanism identification.
• Liquid biopsy, analyzing blood for CTCs or cell-free DNA, provides novel diagnostic approaches.

Conclusions:

• Liquid biopsy represents a significant advancement in cancer diagnostics, offering non-invasive methods for monitoring disease.
• Further research and conceptual frameworks are needed to overcome current challenges and fully realize the clinical potential of CTCs and ctDNA.
• The integration of CTC and ctDNA analysis into clinical practice holds the potential to revolutionize cancer care from detection to treatment response assessment.